Atlas Trials

A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

Clinical trial NCT04566692 · COMPLETED

Trial details

NCT number
NCT04566692
Sponsor
Grifols Therapeutics LLC
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Primary Immunodeficiency
Start date
2020-11-24
Primary completion
2022-07-18
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.